FLUOROPHARMA MEDICAL.........

to the Medical Imaging & Technology Alliance (MITA)


MONTCLAIR, NJ--(Marketwired - November 25, 2013) - FluoroPharma Medical, Inc. (FPMI), a company specializing in the development of novel diagnostic imaging products that utilize positron emission tomography (PET) technology for the detection and assessment of disease before clinical manifestation, announced today that it has been elected to MITA and will be represented by Edward L. Lyons, Vice President of Marketing. Mr. Lyons is responsible for the global development and commercial strategy for FluoroPharma's nuclear cardiology portfolio.

MITA, a division of the National Electrical Manufacturers Association (NEMA), is the leading organization and collective voice of medical imaging equipment, radiation therapy and radiopharmaceutical manufacturers, innovators and product developers. It represents companies whose sales comprise more than 90 percent of the global market for medical imaging technology.

"FluoroPharma is pleased and proud to become a member of this important organization. MITA is a key advocate for our industry as medical diagnostic products are playing an ever increasing role in the detection, diagnosis and treatment of disease. We are delighted to have Ed Lyons represent both our company as well as cardiac patients' interests at MITA," said FluoroPharma's Chairman and CEO Thijs Spoor.

"The policy landscape for diagnostics has become more complicated. Diagnostics are highly valued, therefore highly utilized," said Mr. Lyons. "Because they are highly utilized, they are the subject of far more scrutiny than in the past. We believe that as a member company of MITA, we will share in the collective knowledge, experience, and support of the Molecular Imaging community to develop our diagnostic products in a way that clearly demonstrates their clinical and economic value in cardiovascular disease."

About FluoroPharma Medical
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology from the Massachusetts General Hospital in Boston.

The Company's goal is to enable personalized medicine through precision diagnostics that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

FluoroPharma's initial focus is the development of breakthrough positron emission tomography (PET) imaging agents and is advancing two products in clinical trials for assessment of acute and chronic forms of coronary artery disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image brain tissue affected by Alzheimer's disease and agents that could potentially be used for imaging specific cancers.

In addition to the United States, Europe and China, patents related to FluoroPharma's portfolio of imaging compounds have been issued in Japan, Canada, Australia, Finland, Portugal, Ireland and Mexico.

For more information on the Company, please visit: www.fluoropharma.com

Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding FluoroPharma's research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma's filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:
CONTACT:

Media:
Carol J. Perlman
FluoroPharma Medical, Inc.
cperlman@fluoropharma.com
Phone: 917-592-9260

Investor Relations:
Richard Moyer
Cameron Associates, Inc.
Richard@cameronassoc.com
Phone: 212-554-5466
http://finance.yahoo.com/news/...l-inc-elected-medical-145352615.html  

http://finance.yahoo.com/q/is?s=fpmi GrB  

Market Cap (intraday)5: 14.15M
Enterprise Value (Nov 27, 2013)3: 10.59M
Trailing P/E (ttm, intraday): N/A
Forward P/E (fye Dec 31, 2014)1: N/A
PEG Ratio (5 yr expected)1: N/A
Price/Sales (ttm): N/A
Price/Book (mrq): 17.97
Enterprise Value/Revenue (ttm)3: NaN
Enterprise Value/EBITDA (ttm)6: -2.42
http://finance.yahoo.com/q/ks?s=FPMI+Key+Statistics  

Fiscal Year
Fiscal Year Ends: Dec 31
Most Recent Quarter (mrq): Sep 30, 2013
Profitability
Profit Margin (ttm): N/A
Operating Margin (ttm): N/A
Management Effectiveness
Return on Assets (ttm): -115.86%
Return on Equity (ttm): -512.93%
Income Statement
Revenue (ttm): N/A
Revenue Per Share (ttm): N/A
Qtrly Revenue Growth (yoy): N/A
Gross Profit (ttm): N/A
EBITDA (ttm)6: -4.37M
Net Income Avl to Common (ttm): -6.09M
Diluted EPS (ttm): -0.25
Qtrly Earnings Growth (yoy): N/A
Balance Sheet
Total Cash (mrq): 3.37M
Total Cash Per Share (mrq): 0.14
Total Debt (mrq): 55.00K
Total Debt/Equity (mrq): 6.98
Current Ratio (mrq): 1.20
Book Value Per Share (mrq): 0.03
Cash Flow Statement
Operating Cash Flow (ttm): -2.83M
Levered Free Cash Flow (ttm): 856.66K
http://finance.yahoo.com/q/ks?s=FPMI+Key+Statistics  

a: -0.01
52-Week Change3: -20.55%
S&P500 52-Week Change3: 27.86%
52-Week High (Jan 3, 2013)3: 0.95
52-Week Low (Nov 11, 2013)3: 0.48
50-Day Moving Average3: 0.59
200-Day Moving Average3: 0.64
http://finance.yahoo.com/q/ks?s=FPMI+Key+Statistics  

Avg Vol (3 month)3: 26,012
Avg Vol (10 day)3: 7,371
Shares Outstanding5: 24.39M
    Float:    16.49M§
% Held by Insiders1: N/A
% Held by Institutions1: N/A
Shares Short 3: N/A
Short Ratio 3: N/A
Short % of Float 3: N/A
Shares Short (prior month)3: N/A
http://finance.yahoo.com/q/ks?s=FPMI+Key+Statistics  

http://finance.yahoo.com/q/rr?s=FPMI+Research+Reports GrB  

http://finance.yahoo.com/q/p?s=FPMI+Press+Releases GrB  

company, discovers, develops, and commercializes medical diagnostic imaging products to evaluate cardiac disease at the cellular and molecular levels. The company focuses on the development of positron emission tomography (PET) imaging agents for the detection and assessment of acute and chronic forms of coronary artery disease. It offers PET scan imaging agents that include CardioPET, a modified fatty acid that provides insight into regions with decreased blood flow or metabolic insufficiency in the myocardium; BFPET, a flourine-18 labeled tracer that enters the myocardial cells in direct proportion to blood flow and cell membrane potential; VasoPET, an imaging agent that targets active molecule receptors associated with inflammatory conditions to visualize areas in the blood vessels that may initiate thrombosis and embolism; and AZPET, an imaging agent that attaches to amyloid deposits (plaque) in the brain and makes them visible on a PET scan for the early detection of Alzheimer’s disease. The company serves molecular imaging, cardiovascular, and other diagnostic markets in the United States, Canada, Mexico, China, Japan, and Australia; and Finland, Portugal, Ireland, and other European countries through stock brokers and online trading accounts. FluoroPharma Medical, Inc. was formerly known as FluoroPharma, Inc. and changed its name to FluoroPharma Medical, Inc. in May 2011. The company was founded in 2003 and is headquartered in Montclair, New Jersey.
http://finance.yahoo.com/q/pr?s=FPMI+Profile  

Website: http://www.fluoropharma.com

buran und MfG und schüddelböööööön  

:::::::::::::::::: 0,60 $ +3,45% +0,02 $
In Euro: 0,4412 € | Nasdaq OTC BB, 27.11.13 ,GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  29.11.13      0,60      0,60§0,60 0,60 $ 2.000 1.200

GrB  

Zeit      Kurs Stück
  21:54:20§0,59 $ 10.000
_____________________
GRATULATION  

Zeit       Kurs Stück
  18:21:56§0,55 $ 555
  18:17:43§0,55 $ 600
  17:57:22§0,57 $ 5.000
  17:02:08§0,57 $ 11.500
  17:02:00§0,5503 $ 5.000

buran und MfG und danke und TOP  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  15.01.14      0,70      0,72§0,65 0,65 $ 319.007 212 T
  14.01.14      0,72      0,72§0,66 0,70 $ 198.575 136 T
  13.01.14      0,75      0,76§0,67 0,68 $ 293.030 204 T
  10.01.14      0,60      0,76§0,55 0,76 $ 197.728 105 T
  09.01.14      0,57      0,59§0,5201 0,5201 $ 30.422 17.204
  08.01.14    0,5701      0,59§0,55 0,55 $ 45.900 25.953
  07.01.14      0,59      0,59§0,59 0,59 $ 5.000 2.950
  06.01.14      0,58      0,58§0,58 0,58 $ 3.600 2.088
  03.01.14      0,60      0,60§0,55 0,5701 $ 24.820 14.034
  02.01.14    0,6399    0,6399§0,60 0,60 $ 13.468 8.287

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  17.01.14      0,70      0,70§0,66 0,68 $ 122.800 83 T

GrB  

SK 0,68 $ SKP +0,00 Pott +25,93% buran und MfG
 

::::::::::::::::: 0,67 $ +3,08% +0,02 $
In Euro: 0,4966 € | Nasdaq OTC BB, 31.01.14:::::::: Kosmonova buran und MfG und danke und SCHICK  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  28.02.14      0,56      0,60§0,536 0,54 $ 279.735 155 T
  27.02.14     0,525      0,57§0,51 0,57 $ 313.750 168 T
  26.02.14     0,541      0,55§0,51 0,51 $ 145.556 77 T
  25.02.14      0,55      0,57§0,531 0,55 $ 179.409 92 T
  24.02.14     0,561     0,561§0,531 0,55 $ 123.427 68 T
  21.02.14     0,551      0,56§0,531 0,55 $ 109.500 60 T
  20.02.14     0,561      0,58§0,551 0,551 $ 67.590 38.129
  19.02.14      0,57     0,578§0,551 0,551 $ 116.235 66 T
  18.02.14      0,54      0,60§0,54 0,55 $ 64.317 36.050
  14.02.14      0,53      0,54§0,51 0,52 $ 148.280 77 T
  13.02.14      0,51      0,53§0,4701 0,53 $ 150.760 75 T
  12.02.14      0,52      0,53§0,51 0,51 $ 118.930 62 T
  11.02.14     0,522      0,54§0,51 0,52 $ 326.070 172 T
  10.02.14      0,55      0,57§0,508 0,549 $ 208.747 114 T
  07.02.14      0,59      0,59§0,535 0,55 $ 315.027 173 T
  06.02.14      0,64      0,69§0,52 0,60 $ 450.617 280 T
  05.02.14     0,635      0,64§0,621 0,64 $ 107.120 68 T
  04.02.14      0,64      0,68§0,623 0,63 $ 360.766 236 T
  03.02.14      0,67      0,67§0,63 0,63 $ 92.416 55 T

buran und MfG und danke und weitermachen  

:::::::::::::::::: 0,72 $ +0,70% +0,005 $

In Euro: 0,5219 € | Nasdaq OTC BB, 21.03.14::::: und Du bist nicht dabei... boaa ..::Kosmonova buran ..::hopshopshopshopshopshops HALLO  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  16.05.14     0,743     0,747§0,735 0,735 $ 21.578 15.955

GrB  

Datum Erster Hoch Tief Schluss     Stücke Volumen
  05.08.14      0,56      0,59§0,56 0,56 $ 54.715 31.405

GrB  

::::::::::::: 0,60 $ +3,45% +0,02 $
In Euro: 0,4666 € | Nasdaq OTC Other, 18.09.14:::::: Bouche  

buran: nur ein börsenboard geführt von www.bundesbank.de 21:18 #1
achte er einfach auf die links
Mit freundlichen Grüssen Mario Meierhof 39517 Lüderitz Gartenstrasse 6
mariomeierhof@web.de
Tel.:039361/96548 Atelier Meierhof 039361/51273 Kuhle
gez MARIO alias buran http://www.ariva.de/…/nur-ein-boersenboard-gefuehrt-von-www…

Deutsche Bundesbank - Startseite
Die Deutsche Bundesbank ist die Zentralbank der Bundesrepublik Deutschland. Zentrales Geschäftsfeld ist die Geldpolitik des Eurosystems.
BUNDESBANK.DE
https://www.facebook.com/mario.meierhof  

Abkürzung für Federal Openmarket Committee
http://www.ariva.de/extras/lexikon.m?begriff=FOMC